Remove 2024 Remove Family Remove Family Doctor Remove Family Physician
article thumbnail

Is there enough time for prevention in primary care?

Common Sense Family Doctor

Family physicians are being squeezed by two accelerating trends: (1) too few of us to care for the growing US population and (2) the rising number of tasks that we are asked to accomplish for each patient. Since 2020, the starting ages for breast, lung, and colorectal cancer screening were lowered to 40, 50, and 45 years, respectively.

article thumbnail

How to Get Rid of Old/Unused Medicines

Noreta Family Medicine

As a family doctor, I hear my patients talk about their “medicine cabinet full of old medicines” all the time. Even if you don’t flush your meds, chances are that someone in your family, a neighbor, etc. Let’s reduce the amount of medicine getting into our South Carolina water system and help keep our friends and family safe!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Migraine headaches: diagnostic and treatment tips

Common Sense Family Doctor

An article on acute migraine headaches in the April 2025 issue of American Family Physician reviewed current treatment strategies for acute migraine headaches, which “account for … 3.6 million primary care visits annually and are the fifth most common reason for emergency department visits” in the United States.

article thumbnail

Measles, vaccine hesitancy, and the ACIP

Common Sense Family Doctor

For comparison, there were 285 cases of measles in the United States in 2024, and there have already been more reported cases than in all but two years since 2000. In a 2024 American Family Physician editorial , Dr. Doug Campos-Outcalt reviewed best practices for diagnosis and prevention of measles.

article thumbnail

Direct-to-consumer advertising distorts prescription drugs’ benefits and costs

Common Sense Family Doctor

In 1998, a Letter to the Editor in American Family Physician expressed concerns about the relatively new practice of pharmaceutical advertising directly to patients. In November 2024, a new U.S.